University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Israel-based dermatology focussed biotech Sol-Gel Technologies says it has acquired rights to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from US drug developer PellePharm. 30 January 2023
The US Food and Drug Administration (FDA) has granted accelerated approval to Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma (MCL) - a rare blood disorder - after at least two lines of systemic therapy, including a BTK inhibitor. 28 January 2023
The US Food and Drug Administration (FDA) on Friday announced the approval of the investigational oral selective estrogen receptor degrader (SERD) Orserdu (elacestrant) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. 28 January 2023
The European Medicines Agency (EMA) has issued an update on ongoing shortages of antibiotic medicines containing amoxicillin—alone and in combination with clavulanic acid. 27 January 2023
Research from the IQVIA Institute for Human Data Science shows that total spending and global demand for medicines could hit $1.9 trillion by 2027. 27 January 2023
An interview reflecting on 2022 and looking forward to the year ahead with Paul O'Donohoe senior director, eCOA Product and Science at Medidata. 26 January 2023
Pharma industry analyst GlobalData has highlighted the strength of data supporting a submission from US biotech Intercept Pharmaceuticals in non-alcoholic steatohepatitis (NASH). 26 January 2023
On December 23 2022, the FDA Modernization Act 2.0 was passed with full support from both the US House of Representatives and the Senate.1 This act aims to improve the process for approving drugs and commits to significantly reducing the use of dogs, primates, and other animals in laboratory testing. 26 January 2023
Shares of US retinal eye disorder specialist Ocuphire Pharma slumped more than 29% to $2.66, after it released disappointing top-line efficacy and safety results from its ZETA-1 Phase II trial evaluating oral APX3330 for the treatment of diabetic retinopathy (DR). 26 January 2023
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee has voted favorably, by 14 to 1, that Cidara Therapeutics, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin. 25 January 2023
US drugmaker Eli Lilly is to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company's Research Triangle Park facility in North Carolina. 25 January 2023
The Chinese Center for Disease Control and Prevention has recorded that Omicron lineages BA.5.2 and BF.7 account for 97.5% of all local infections in the country. 25 January 2023
The US Department of Health and Human Services (HHS) yesterday issued a new report showing the major savings coming to people with Medicare thanks to the $35 cap on a month’s supply of insulin. 25 January 2023
Revenues in the fourth quarter came in below expectations for Johnson & Johnson, with the company reporting sales of $23.7 billion, a decline of 4.4%. 24 January 2023
A new chief executive is to take over from Jeff Hatfield at Vividion Therapeutics, Bayer’s wholly-owned subsidiary that is using discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. 24 January 2023
The European Commission Decision Reliance Procedure (ECDRP) has been extended to December 31, 2023, when a new international recognition framework will be in place, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) announced today. 24 January 2023
In a sudden turn of events, Novartis' Entresto (sacubitril/valsartan) patent has been reinstated in India, after a two-judge bench stayed a previous order that invalidated it. 24 January 2023
Shares of US clinical-stage biotech Axcella Therapeutics were up nearly 70% at $0.72 pre-market this morning, after it announced a regulatory path to registration of AXA1125 in the treatment of long COVID fatigue. 24 January 2023
In the context of a sagging economy and a multitude of economic woes, lawmakers in the UK may be receptive to news of the potential for medicines manufacturing to boost growth. 24 January 2023
Israel-based computational disease modelling company CytoReason and French pharma major Sanofi have announced an expansion of their collaboration. 23 January 2023